EGFR and neoplasm: Currently, various monoclonal antibodies targeting either EGFR, including the therapeutic antibodies panitumumab (37), necitumumab (38), nimotuzumab (39) and cetuximab (40), or PD-L1, among them durvalumab (41), avelumab (42) and atezolizumab (43) are approved for tumor treatment in multiple countries.